Trials / Completed
CompletedNCT00095810
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aripiprazole | Tablets, Oral, 1-10mg, Once daily, 6 weeks. |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2004-09-01
- Completion
- 2004-09-01
- First posted
- 2004-11-09
- Last updated
- 2013-11-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00095810. Inclusion in this directory is not an endorsement.